ECOG-ACRIN EA5142 - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

https://clinicaltrials.gov/ct2/show/NCT02595944

ECOG-ACRIN EA5142
Cancer
Mehul Patel, MD
Enrolling
Rachel O’Loughlin, RN BSN
(585) 747-4555